Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263246 | 0.88 | KDM4E (0.35) | HDAC8RAB9A | |
| SCHEMBL453032 | 0.78 | KDM4E (0.31) | MEN1RAB9AKMT2A | |
| SCHEMBL450265 | 0.77 | NPC1 (0.31) | RAB9A | |
| SCHEMBL452380 | 0.74 | NPC1 (0.37) | MEN1RAB9AKMT2AACHE | |
| SCHEMBL449177 | 0.72 | SMN1; SMN2 (0.44) | MEN1RAB9AKMT2AACHETSHR | |
| SCHEMBL448360 | 0.72 | SMN1; SMN2 (0.44) | MEN1RAB9AKMT2AACHETSHR | |
| SCHEMBL452117 | 0.72 | SMN1; SMN2 (0.44) | MEN1RAB9AKMT2AACHETSHR | |
| SCHEMBL3521680 | 0.72 | — | — | |
| SCHEMBL452206 | 0.72 | SMN1; SMN2 (0.44) | MEN1RAB9AKMT2AACHETSHR | |
| SCHEMBL3719754 | 0.71 | HDAC8 (0.55) | HDAC8MEN1PABPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065181-A1 | METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY | 2012-03-15 | — | — | US | disclosed |
| US-20080113956-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113956-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | HDAC8 4371/4885MEN1 3668/4885PABPC1 3022/4885 |
| US-20120065181-A1 | METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS | SOD1, PYGB, PSAP | HDAC8 857/4885MEN1 3567/4885PABPC1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.